Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 10-Hour eating window fight cancer fatigue?

NCT ID NCT07826871

Symptom relief Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are testing whether time-restricted eating, where all food is eaten within a 10-hour window each day, can reduce fatigue and slow frailty in older adults living with prostate cancer or metastatic breast cancer. The trial enrolls 132 people aged 55 and older who typically eat over a window longer than 12 hours. Participants are randomly assigned to either time-restricted eating or nutrition counseling based on American Cancer Society guidelines. The study measures fatigue, frailty, circadian rhythms, and how the body responds to everyday physical changes over 12 weeks, with follow-up at 6 and 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
time-restricted eating, a daily eating pattern with a 10-hour window, compared with nutrition counseling
What this could lead to
If it works, time-restricted eating could offer an inexpensive, scalable way to ease fatigue and slow frailty in older adults living with cancer as a chronic condition.
What could go wrong
This is a phase 2 trial with 132 participants, so any benefit may be modest or may not hold in a larger study. Changing eating habits can be hard to stick with, and the approach may not help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of prostate cancer or metastatic breast cancer * Have current use or a history of hormone therapy (e.g., androgen deprivation therapy, aromatase inhibitors) * Have a life expectancy of ≥1 year * Be 55 years of age or older * Typically consume food within a window that is greater than 12 hours * Be able to communicate in English * Have a body mass index (BMI) ≥18.5 kg/m\^2 Exclusion Criteria: * Be employed in overnight shift work more than 1 day/week on average * Be on enteral or parenteral nutrition * Have any contraindications to the proposed intervention as identified by their medical provider (e.g., type 1 diabetes, pregnancy, recent history of an eating disorder, recent bariatric surgery, insulin dependency) * Have had time zone travel ≥2 time zones away within the last 4 weeks, or have time zone travel (≥2 time zones away) planned for more than 2 days in the next 14 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatigue in cancer survivors are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty Intermittent Fasting prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatigue in cancer survivors

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Maryland, Baltimore

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.